Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.67 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.63 |
| ▸ | SRC | P12931 | 5/20 | 0.62 |
| ▸ | RAF1 | P04049 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6380567 | 0.91 | EGFR (0.79) | EGFRERBB2MAP2K1SRCRAF1 | |
| SCHEMBL23730429 | 0.85 | SRC (0.64) | EGFRERBB2SRC | |
| SCHEMBL6381464 | 0.81 | EGFR (1.00) | EGFRERBB2MAP2K1SRCRAF1 | |
| SCHEMBL6381317 | 0.80 | EGFR (1.00) | EGFRERBB2MAP2K1SRCRAF1 | |
| SCHEMBL6382822 | 0.79 | MAP2K1 (0.78) | EGFRERBB2MAP2K1SRCRAF1 | |
| SCHEMBL23730140 | 0.79 | EGFR (0.62) | EGFRERBB2MAP2K1SRCRAF1 | |
| SCHEMBL6381609 | 0.78 | EGFR (1.00) | EGFRERBB2MAP2K1SRCRAF1 | |
| SCHEMBL5733290 | 0.77 | MAP2K1 (1.00) | EGFRERBB2MAP2K1SRCRAF1 | |
| SCHEMBL6380423 | 0.77 | EGFR (1.00) | EGFRERBB2MAP2K1SRC | |
| SCHEMBL28756490 | 0.77 | MAP2K1 (0.95) | EGFRERBB2MAP2K1SRCRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021155144-A1 | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCERS WITH NRG1 FUSIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-08-05 | — | — | WO | disclosed |